Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan;19(1 Suppl):S102-8.
doi: 10.1016/j.bbmt.2012.10.028. Epub 2012 Oct 27.

Graft-versus-host disease: state of the science

Amin M Alousi  1 , Javier Bolaños-Meade, Stephanie J Lee
Affiliations
Review

Graft-versus-host disease: state of the science

Amin M Alousi et al. Biol Blood Marrow Transplant. 2013 Jan.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schema of 4 novel GVHD prophylaxis regimens. (A) Pentostatin with tacrolimus/MTX. (B) Cyclophosphamide with or without tacrolimus/MMF. (C) Bortezomib with tacrolimus/MTX. (D) Maraviroc with tacrolimus/MTX.
Figure 2
Figure 2
BMT CTN GVHD Prophylaxis Trial: randomized Phase II with CIBMTR matched controls.
See this image and copyright information in PMC

References

    1. Cutler C, Stevenson K, Kim HT, et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008;112:4425–4431. - PMC - PubMed
    1. Pasquini MC, Devine S, Mendizabal A, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. / Gin Oncol. 2012;30:3194–3201. - PMC - PubMed
    1. Bayraktar UD, De Lima M, Rima SM, et al. Ex vivo T celledepleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission: a comparison of outcomes in two institutions. Blood (ASH Annual Meeting Abstracts) Nov 2011. 2013;118
    1. Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophylaxis with or without anti—T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol. 2009;10:855–864. - PubMed
    1. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti–T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117:6963–6970. - PMC - PubMed

Publication types

LinkOut - more resources